Skip to main content
. 2021 Sep 17;9:736994. doi: 10.3389/fcell.2021.736994

TABLE 1.

Clinical characteristics of participants.

Indexes Tumor patients Reference range
Age (years) 58.40 ± 2.36
Gender
Female 10 (50%)
Male 10 (50%)
Location of tumor
Proximal colon 4(20%)
Distal colon 8 (40%)
Rectum 8 (40%)
TNM
0–II 14 (70%)
III–IV 6 (30%)
Blood pressure
Hypertension 7 (35%)
Normotension 13 (65%)
LNM
Yes 6 (30%)
No 14 (70%)
BMI, kg/m2 22.68 ± 3.53
Laboratory parameters (M ± Q)
Glu, mmol/L 6.14 ± 1.50 3.90–6.10
T-CH, mmol/L 4.56 ± 0.63 3.10–5.71
TG, mmol/L 1.81 ± 0.35 0.58–1.70
HDL, mmol/L 1.25 ± 0.26 0.91–1.55
LDL, mmol/L 2.77 ± 0.47 2.07–3.12
CEA, μg/L 4.39 ± 5.97 0–5
CA-19-9, U/ml 155.09 ± 585.59 0–37
TBA, μmol/L 4.78 ± 4.87 0–10
LDH, U/L 180.30 ± 46.00 120.0–250.0
ADA, U/L 10.05 ± 3.08 0–25
NEUT#, 109/L 4.40 ± 1.49 1.8–6.3
LY#, 109/L 1.52 ± 0.44 1.1–3.2
PLT, 109/L 275.45 ± 78.40 125–350
NLR 3.35 ± 2.28
PLR 199.43 ± 90.07

TNM, tumor–node–metastasis; LNM, lymph node metastasis; BMI, body mass index; Glu, glucose; T-CH, total cholesterol; TG, triglyceride; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; CEA, carcinoembryonic antigen; CA199, carbohydrate antigen 19-9; TBA, total bile acid; LDH, lactate dehydrogenase; ADA, adenosine deaminase; NEUT#, neutrophils; LY#, lymphocyte; PLT, platelet count; NLR, neutrophil–lymphocyte ratio; PRL, platelet-to-lymphocyte ratio.